Patent · US Active

Antidiabetic bicyclic compounds

US10968193B2 · kind B2 · utility

1Cited by

3References

11Claims

0Family size

Assignee

Merck Sharp & Dohme LLC · US

Inventors

Helen Chen · Livingston, US
Steven L. Colletti · Princeton Junction, US
Duane DeMong · Somerville, US
Yan Guo · Westfield, US
Michael Miller · Scotch Plains, US
Anilkumar G. Nair · Edison, US
Christopher W. Plummer · Hoboken, US
Dong Xiao · Hackettstown, US
De-Yi Yang · Morristown, US

Key dates

Filing date	Aug 6, 2015
Grant date	Apr 6, 2021
Priority date	—
Expiry date	Aug 21, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D491/107
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.